Nabilone controlled release - AOP Orphan Pharmaceuticals

Drug Profile

Nabilone controlled release - AOP Orphan Pharmaceuticals

Alternative Names: Nabilone FDT

Latest Information Update: 20 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AOP Orphan Pharmaceuticals AG
  • Developer AOP Orphan Pharmaceuticals AG; Innsbruck Medical University
  • Class Antiemetics; Cannabinoids; Non-opioid analgesics; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Parkinson's disease
  • Phase II Pain

Most Recent Events

  • 13 Apr 2018 Phase-III clinical trials in Parkinson's disease (In the elderly, Second-line therapy or greater, In adults) in Austria (PO) (EudraCT2017-004253-16)
  • 15 Sep 2017 Phase-II clinical trials in Parkinson's disease (In adults, In the elderly, Second-line therapy or greater) in Austria (PO) (EudraCT2017-000192-86)
  • 10 Jun 2016 Orthopädisches Spital Speising GmbH and AOP Orphan Pharmaceuticals initiate the pilot phase II Cannabinoid-Spinal-Fusion-Study trial for Pain in Austria (PO, Capsule) (EudraCT2015-004227-31)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top